ArticleRespiratory research2026
Proteo-metabolomic insights into the progression of chronic obstructive pulmonary disease and lung function decline.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploration of network-based, machine learning, MD simulations, and MM/GBSA approaches revealed luteolin from Gynura procumbens as key inhibitor of MMP9 in NSCLC.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a progressive yet preventable respiratory disease, often remaining undiagnosed until significant lung function impairment has occurred. The early, asymptomatic stage, termed "pre-COPD", offers a critical window for intervention, yet its molecular characteristics remain poorly understood.
methodsWe performed integrated proteomic and metabolomic profiling of human lung tissues across the spectrum of COPD (n = 32), including non-diseased controls, individuals with pre-COPD, and patients at varying stages of established disease. Key molecules and pathways involving in the progression of COPD were revealed. The performance of candidate biomarkers for monitoring early-stage lung function decline was validated in serum samples from an independent cohort (n = 158), and a longitudinal cohort from the UK Biobank (n = 21,686).
resultsPairwise comparisons revealed 751 proteins and 1,024 metabolites that were differentially abundant among groups. Pathways such as pyrimidine metabolism and arginine biosynthesis were revealed associated with disease progression. Notably, we identified a core protein-protein interaction network modulated by zinc and copper, two clinically used, orally available trace elements, highlighting their potential as candidate therapeutic agents for COPD. Furthermore, integrative analysis with an independent blood-based cohort and longitudinal data from the UK Biobank uncovered choline as a circulating biomarker that predicts longitudinal lung function decline.
conclusionOur findings define a molecular atlas of pre-COPD, identify actionable therapeutic targets, and propose a readily measurable biomarker for early detection and risk stratification of COPD.
Indexed as
Identifiers
42387628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.